GLP-1 weight-loss drugs boost demand for premium New Zealand protein and fruit exports
A Rabobank report says the surge in GLP-1 weight-loss medication is driving health-focused consumers toward New Zealand’s high-quality protein and fruit products.
Rabobank’s "New Zealand's protein moment" report finds that GLP-1 weight-loss medications are accelerating demand for high-quality protein as consumers seek to preserve lean muscle while eating less. Global shortages of beef and sheep meat are supporting strong farm-gate prices, but long-term growth will depend on market diversification and validated nutrition claims. Senior animal protein analyst Jen Corkran notes that the market signal is for useful, high-quality protein rather than simply more meat. Premium fruit companies, including Rockit Apples and Zespri, say the GLP-1 trend is boosting interest in their nutrient-rich, convenient snack offerings, especially in markets like Singapore where consumers demand science-backed health benefits.
Why it matters
The story shows how a new class of weight-loss drugs is reshaping global food demand, creating export opportunities for New Zealand producers.
In this story
